| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2407405 | Vaccine | 2009 | 8 Pages |
The total cost of HPV-related diseases accounts for €200–250 million of which €210 million is absorbed by the prevention and treatment of precancerous lesions and cervical cancer.Although both available HPV vaccines are below the threshold value for economic convenience (€9,569 and €26,361 per QALY-gained for the quadrivalent and bivalent vaccines, respectively), at this point in time long-term economic models developed for Italy seem to indicate the quadrivalent vaccine as the most cost-effective option.Recent publications by official bodies, including the World Health Organization and the Supervisory Authority for Public Contracts in Italy, recommend that the decision-making process be based on both the quality of goods and services as well as the best achievable price.
